N
SUPN icon

Natixis’s Supernus Pharmaceuticals SUPN Stock Holding History

Natixis’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-85,200
Closed -$4.4M – 1357
2026
Q1 		$4.4M Buy
+85,200
New +$4.34M 0.02% 458
2021
Q1 		– Sell
-49,000
Closed -$1.23M – 1183
2020
Q4 		$1.23M Buy
+49,000
New +$1.05M ﹤0.01% 768

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Natixis's SUPN Position: Q2 2026 in Review

Natixis sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 85,200 shares — an estimated $4.4M sold.

Natixis first reported a position in SUPN in Q4 2020 and held it in 2 quarters. The position peaked at $4.4M in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Natixis reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 85,200 Supernus Pharmaceuticals shares in Q2 2026, an estimated $4.4M.
  • Natixis first reported a position in Supernus Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Natixis's Supernus Pharmaceuticals position peaked at $4.4M in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.